The safety data of Dupilumab for the treatment of moderate-to-severe atopic dermatitis in infants, children, adolescents, and adults
Open accessAbstract
Atopic dermatitis (AD) significantly affects quality of life in patients of all ages and requires long-term treatment. Dupilumab is approved for uncontrolled moderate-to-severe AD in patients aged ≥ 6 months and in other type 2 inflammatory diseases. Data from placebo-controlled, randomized clinical trials (RCTs) and long-term open-label extensions (OLEs) enable comprehensive assessment of dupilumab’s safety profile for up to 5 years. To integrate short- and long-term dupilumab safety data in patients with moderate-to-severe AD. We describe safety from eight phase 3 trials with > 7000 patient-years of dupilumab use: five 16-week RCTs in children (6 months–11 years, with concomitant topical corticosteroids [TCS]) and adolescents and adults (≥ 12 years, without TCS); one 52-week RCT in adults (with TCS); and two OLEs in children and adolescents (6–11- and 12–18-year cohorts, ± TCS, duration ≤ 1 year) and adults (± TCS, duration ≤ 5 years). The proportion of patients experiencing ≥ 1 treatment-emergent adverse event (TEAE) in RCTs was lower with dupilumab versus placebo in children/infants and was similar with dupilumab versus placebo in adults/adolescents. Exposure-adjusted incidence rates with longer-term treatment in OLEs were similar to the RCTs. Most TEAEs reported in RCT and OLE studies were mild to moderate and not related to study drug (per investigators). Fewer patients in the dupilumab versus placebo treatment arms experienced serious TEAEs (16-week RCTs: infants/children 0.8% vs 3.0%; adults/adolescents 2.0–2.2% vs 4.6%; 52-week RCT: 3.2–3.6% vs 5.1%). Common TEAEs that had higher incidence rates with dupilumab compared with placebo in RCTs included injection-site reactions (Medical Dictionary for Regulatory Activities High Level Term) and conjunctivitis (clustered term). Serious infections and non-herpetic skin infections were more frequent with placebo. In the most comprehensive dupilumab safety assessment to date, safety was consistent with the known dupilumab safety profile. [Graphical abstract and video abstract available.] ClinicalTrials.gov Identifiers: NCT03346434; NCT03345914; NCT03054428; NCT02277743; NCT02277769; NCT02260986; NCT01949311; NCT02612454. EudraCT: 2016-000955-28; 2016-004997-16; 2015-004458-16; 2014-001198-15; 2014-002619-40; 2013-003254-24; 2013-001449-15; 2015-001396-40. Atopic dermatitis is a chronic skin disease that affects people of all ages. Since patients with atopic dermatitis require continuous, life-long treatment, doctors and patients must understand the risks and benefits of treatment options before choosing one medication over another. This study reviews the safety of the drug dupilumab, which is used to treat infants, children, adolescents, and adults who have moderate-to-severe atopic dermatitis that is not well controlled with topical corticosteroids. We looked at side effects and safety data from more than 4000 patients who received either dupilumab or placebo treatment for up to 5 years in eight clinical trials. This study is the largest safety analysis of dupilumab to date. We found that children 6 months to 11 years receiving dupilumab had fewer side effects than patients in the placebo group. Adolescents and adults (12 years and older) taking dupilumab and placebo had similar rates of side effects. Serious side effects were more frequent in the placebo than in the dupilumab group in all age groups. Most side effects in patients who received dupilumab were mild or moderate, were not caused by dupilumab, and did not stop patients from taking dupilumab. The most common side effects that occurred more frequently in dupilumab-treated patients were pain or swelling around the injection location, common colds, and conjunctivitis. In conclusion, the safety of dupilumab in over 3000 patients in this study is consistent with the known dupilumab safety profile for infants, children, adolescents, and adults.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Skin diseases, including chronic inflammatory conditions like eczema and psoriasis, are widespread globally and can impose a significant disease burden, especially in moderate-to-severe symptoms.
“Skin diseases, including chronic inflammatory conditions like eczema and psoriasis, are widespread globally and can impose a significant disease burden, especially in their moderate-to-severe symptoms (15).”
From Revolutionizing dermatopathology using AI in skin diagnostics: scoping review (2026) · cites this paper as [15]
The Introduction (page not provided) describes atopic dermatitis, or eczema, as an inflammatory skin disease affecting people of all ages and says moderate-to-severe disease carries a high burden. It does not establish that skin diseases are widespread globally or address psoriasis, so the citation supports only the eczema-burden portion of the sentence. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · see citing works
Self-citationBachert, C., Han, J. K., Desrosiers, M. Y., Hellings, P. W., Amin, N., Lee, S. E., Mullol, J., Greos, L. S., Bosso, J. V., Laidlaw, T. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31881-1 · Cited by 1,608 · see citing works
Blauvelt, A., de Bruin-Weller, M. S., Gooderham, M., Cather, J. C., Weisman, J. D., Pariser, D. M., Simpson, E. L., Papp, K. A., Hong, H.-K., Rubel, D. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,260 · see citing works
Self-citationWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181 · see citing works
Bachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794 · see citing works
Targeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766 · see citing works
The burden of atopic dermatitis: summary of a report for the National Eczema Association.
Drucker, A. M., Wang, A. R., Li, W.-Q., Sevetson, E., Block, J. K., & Qureshi, A. A. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.07.012 · Cited by 720 · see citing works
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14888 · Cited by 684 · see citing works
Type 2 cytokines: mechanisms and therapeutic strategies
Wynn, T. A. (2015) · Nature reviews. Immunology · doi:10.1038/nri3831 · Cited by 671 · see citing works
Le Floc’h, A., Allinne, J., Nagashima, K., Scott, G., Birchard, D., Asrat, S., Bai, Y., Lim, W. K., Martin, J., Huang, T., et al. (2020) · Allergy · doi:10.1111/all.14151 · Cited by 545 · see citing works
Simpson, E. L., Paller, A. S., Siegfried, E. C., Boguniewicz, M., Sher, L., Gooderham, M., Beck, L. A., Guttman‐Yassky, E., Pariser, D. M., Blauvelt, A., et al. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3336 · Cited by 532 · see citing works
Self-citationCommonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493 · see citing works
de Bruin-Weller, M. S., Thaçi, D., Smith, C. H., Reich, K., Cork, M. J., Radin, A. R., Zhang, Q., Akinlade, B. K., Gadkari, A., Eckert, L., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16156 · Cited by 479 · see citing works
Self-citationConjunctivitis in dupilumab clinical trials
Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E. L., Blauvelt, A., Cork, M. J., Prens, E., Asbell, P., Akpek, E., Corren, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17869 · Cited by 442 · see citing works
Self-citationEuropean guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Wollenberg, A., Kinberger, M., Arents, B. W. M., ASZODI, N., VALLE, G. L. A., Barbarot, S., Bieber, T. R. M., Brough, H. A., Calzavara‐Pinton, P., Christen-Zäch, S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18345 · Cited by 438 · see citing works
Chu, D. K., Schneider, L. C., Asiniwasis, R. N., Boguniewicz, M., Benedetto, A. D., Ellison, K., Frazier, W. T., Greenhawt, M., Huynh, J., Kim, E., et al. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.11.009 · Cited by 431 · see citing works
Fuxench, Z. C. C., Block, J. K., Boguniewicz, M., Boyle, J. M., Fonacier, L. S., Gelfand, J. M., Grayson, M. H., Margolis, D. J., Mitchell, L., Silverberg, J. I., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.08.028 · Cited by 420 · see citing works
Paller, A. S., Siegfried, E. C., Thaçi, D., Wollenberg, A., Cork, M. J., Arkwright, P. D., Gooderham, M., Beck, L. A., Boguniewicz, M., Sher, L., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.06.054 · Cited by 407 · see citing works
Self-citationSignificance of Skin Barrier Dysfunction in Atopic Dermatitis
Kim, B. E., & Leung, D. Y. M. (2018) · Allergy, Asthma & Immunology Research · doi:10.4168/aair.2018.10.3.207 · Cited by 393 · see citing works
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Boguniewicz, M., Fonacier, L. S., Guttman‐Yassky, E., Ong, P. Y., Silverberg, J. I., & Farrar, J. R. (2017) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2017.10.039 · Cited by 308 · see citing works
Simpson, E. L., Bieber, T. R. M., Eckert, L., Wu, R., Ardeleanu, M., Graham, N. M. H., Pirozzi, G., & Mastey, V. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.10.043 · Cited by 303 · see citing works
Self-citationPaller, A. S., Simpson, E. L., Siegfried, E. C., Cork, M. J., Wollenberg, A., Arkwright, P. D., Soong, W., González, M. E., Schneider, L. C., Sidbury, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01539-2 · Cited by 291 · see citing works
Self-citationBacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review
Ong, P. Y., & Leung, D. Y. M. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8548-5 · Cited by 284 · see citing works
Phenotype of atopic dermatitis subjects with a history of eczema herpeticum
Beck, L. A., Boguniewicz, M., Hata, T. R., Schneider, L. C., Hanifin, J. M., Gallo, R. L., Paller, A. S., Lieff, S., Reese, J., Zaccaro, D. J., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.020 · Cited by 261 · see citing works
Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis
Beck, L. A., Cork, M. J., Amagai, M., Benedetto, A. D., Kabashima, K., Hamilton, J. D., & Rossi, A. B. (2022) · JID Innovations · doi:10.1016/j.xjidi.2022.100131 · Cited by 258 · see citing works
Self-citationDeleuran, M., Thaçi, D., Beck, L. A., de Bruin-Weller, M., Blauvelt, A., Forman, S., Bissonnette, R., Reich, K., Soong, W., Hussain, I., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.074 · Cited by 255 · see citing works
Self-citationYosipovitch, G., Mollanazar, N. K., Ständer, S., Kwatra, S. G., Kim, B., Laws, E., Mannent, L., Amin, N., Akinlade, B. K., Staudinger, H. W., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02320-9 · Cited by 253 · see citing works
Self-citationWechsler, M. E., Klion, A. D., Paggiaro, P., Nair, P. K., Staumont-Sallé, D., Radwan, A., Johnson, R. R., Kapoor, U., Khokhar, F. A., Daizadeh, N. S., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.05.019 · Cited by 250 · see citing works
Self-citationCallewaert, C., Nakatsuji, T., Knight, R. D., Kościółek, T., Vrbanac, A. F., Kotol, P. F., Ardeleanu, M., Hultsch, T., Guttman‐Yassky, E., Bissonnette, R., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.05.024 · Cited by 226 · see citing works
Self-citationBurmester, G. R., Cohen, S. B., Winthrop, K. L., Nash, P. T., Irvine, A. D., Deodhar, A. A., Mysler, E., Tanaka, Y., Liu, J., Lacerda, A. P., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002735 · Cited by 223 · see citing works
Worm, M., Simpson, E. L., Thaçi, D., Bissonnette, R., Lacour, J. ‐., Beissert, S., Kawashima, M., Ferrándiz, C., Smith, C. H., Beck, L. A., et al. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3617 · Cited by 218 · see citing works
Self-citationLegendre, L., Barnetche, T., Mazereeuw‐Hautier, J., Meyer, N., Murrell, D. F., & Paul, C. F. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.02.1116 · Cited by 201 · see citing works
Simpson, E. L., Villarreal, M., Jepson, B. M., Rafaels, N., David, G. L., Hanifin, J. M., Taylor, P. A., Boguniewicz, M., Yoshida, T., Benedetto, A. D., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.03.1517 · Cited by 193 · see citing works
Boguniewicz, M., Alexis, A. F., Beck, L. A., Block, J. K., Eichenfield, L. F., Fonacier, L. S., Guttman‐Yassky, E., Paller, A. S., Pariser, D. M., Silverberg, J. I., et al. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.08.005 · Cited by 190 · see citing works
Burden of Sleep and Fatigue in US Adults With Atopic Dermatitis
Yu, S. H., Attarian, H. P., Zee, P. C., & Silverberg, J. I. (2016) · Dermatitis · doi:10.1097/der.0000000000000161 · Cited by 181 · see citing works
Transplantation of human skin microbiota in models of atopic dermatitis
Myles, I. A., Williams, K. W., Reckhow, J. D., Jammeh, M. L., Pincus, N. B., Sastalla, I., Saleem, D., Stone, K. D., & Datta, S. K. (2016) · JCI Insight · doi:10.1172/jci.insight.86955 · Cited by 180 · see citing works
Ocular complications of atopic dermatitis.
Garrity, J. A., & Liesegang, T. J. (1984) · PubMed · Cited by 164 · see citing works
Facial and neck erythema associated with dupilumab treatment: A systematic review
Jo, C. E., Finstad, A., Georgakopoulos, J. R., Piguet, V., Yeung, J., & Drucker, A. M. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.01.012 · Cited by 160 · see citing works
Wollenberg, A., Beck, L. A., Blauvelt, A., Simpson, E. L., Chen, Z., Chen, Q., Shumel, B. S., Khokhar, F. A., Hultsch, T., Rizova, E., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18434 · Cited by 144 · see citing works
Self-citationBlauvelt, A., Simpson, E. L., Tyring, S. K., Purcell, L. A., Shumel, B. S., Petro, C. D., Akinlade, B. K., Gadkari, A. S., Eckert, L., Graham, N. M. H., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.07.048 · Cited by 138 · see citing works
Self-citationBeck, L. A., Thaçi, D., Deleuran, M. S., Blauvelt, A., Bissonnette, R., de Bruin-Weller, M. S., Hide, M., Sher, L., Hussain, I., Chen, Z., et al. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00527-x · Cited by 138 · see citing works
Self-citationBlauvelt, A., Guttman‐Yassky, E., Paller, A. S., Simpson, E. L., Cork, M. J., Weisman, J. D., Browning, J., Soong, W., Sun, X., Chen, Z., et al. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00683-2 · Cited by 135 · see citing works
Self-citationNomenclature and clinical phenotypes of atopic dermatitis
Girolomoni, G., de Bruin-Weller, M. S., Aoki, V., Kabashima, K., Deleuran, M. S., Puig, L., Bansal, A., & Rossi, A. B. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211002979 · Cited by 130 · see citing works
Self-citationAntimicrobial Peptides, Skin Infections, and Atopic Dermatitis
Hata, T. R., & Gallo, R. L. (2008) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2008.04.002 · Cited by 127 · see citing works
Jones, A. S. C., Prignano, F., Gonçalves, J., Paul, M., & Sewerin, P. (2020) · Rheumatology and Therapy · doi:10.1007/s40744-020-00245-0 · Cited by 124 · see citing works
Berdyshev, E. V., Goleva, E., Bissonnette, R., Bronova, I. A., Bronoff, A. S., Richers, B. N., Garcia, S. L., Ramirez-Gama, M. A., Taylor, P. A., Praestgaard, A. H., et al. (2022) · Allergy · doi:10.1111/all.15432 · Cited by 120 · see citing works
Self-citationAllinne, J., Scott, G. M., Lim, W. K., Birchard, D., Erjefalt, J. S., Sandén, C., Ben, L.-H., Agrawal, A., Kaur, N., Kim, J. H., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.039 · Cited by 118 · see citing works
Impact of atopic dermatitis on quality of life in adults: a systematic review and meta‐analysis
Birdi, G., Cooke, R., & Knibb, R. C. (2020) · International Journal of Dermatology · doi:10.1111/ijd.14763 · Cited by 115 · see citing works
Beck, L. A., Deleuran, M. S., Bissonnette, R., de Bruin-Weller, M. S., Galus, R., Nakahara, T., Seo, S. J., Khokhar, F. A., Vakil, J., Xiao, J., et al. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00685-0 · Cited by 109 · see citing works
Self-citationNarla, S., & Silverberg, J. I. (2017) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2017.10.019 · Cited by 107 · see citing works
Characterizing dupilumab facial redness: A multi-institution retrospective medical record review
Waldman, R. A., DeWane, M. E., Sloan, B., & Grant-Kels, J. M. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.06.026 · Cited by 100 · see citing works
Increased Risk of Cutaneous and Systemic Infections in Atopic Dermatitis—A Cohort Study
Langan, S., Abuabara, K., Henrickson, S. E., Hoffstad, O., & Margolis, D. J. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.01.030 · Cited by 92 · see citing works
Cork, M. J., Thaçi, D., Eichenfield, L. F., Arkwright, P. D., Sun, X., Chen, Z., Akinlade, B. K., Boklage, S., Guillemin, I., Kosloski, M. P., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19460 · Cited by 90 · see citing works
Self-citationPaller, A. S., Siegfried, E. C., Simpson, E. L., Cork, M. J., Lockshin, B., Kosloski, M. P., Kamal, M. A., Davis, J. D., Sun, X., Pirozzi, G., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16928 · Cited by 89 · see citing works
Self-citationA Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis
Kamata, M., & Tada, Y. (2021) · JID Innovations · doi:10.1016/j.xjidi.2021.100042 · Cited by 81 · see citing works
Kou, K., Aihara, M., Matsunaga, T., Chen, H., Taguri, M., Morita, S., Fujita, H., Yamaguchi, Y., Kambara, T., & Ikezawa, Z. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-011-1198-9 · Cited by 77 · see citing works
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis
Beck, L. A., Bissonnette, R., Deleuran, M. S., Nakahara, T., Galus, R., Coleman, A., Gherardi, G., Xiao, J., Dingman, R. K., Xu, C. R., et al. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.1536 · Cited by 75 · see citing works
Self-citationSignificance of Elevated Serum LDH (Lactate Dehydrogenase) Activity in Atopic Dermatitis
Mukai, H., 野口, 俊., Kamimura, K., Nishioka, K., & Nishiyama, S. (1990) · The Journal of Dermatology · doi:10.1111/j.1346-8138.1990.tb01679.x · Cited by 74 · see citing works
Atopic Dermatitis: Epidemiology and Clinical Phenotypes
Raimondo, A., & Lembo, S. (2021) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1104a146 · Cited by 74 · see citing works
Eyerich, K., Gooderham, M., Silvestre, J. F., Shumack, S. P., Mendes‐Bastos, P., Aoki, V., Ortoncelli, M., Silverberg, J. I., Teixeira, H. D., Chen, S. H., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19500 · Cited by 71 · see citing works
Serrano, L., Patel, K. R., & Silverberg, J. I. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.028 · Cited by 67 · see citing works
Reed, J. L., Scott, D. E., & Bray, M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir952 · Cited by 67 · see citing works
Suresh, R., & Murase, J. E. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2018.08.027 · Cited by 59 · see citing works
Jang, D. H., Heo, S., Jung, H. J., Park, M. Y., Seo, S. J., & Ahn, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061982 · Cited by 57 · see citing works
Howell, M. D., Gao, P., Kim, B. E., Lesley, L. J., Streib, J. E., Taylor, P. A., Zaccaro, D. J., Boguniewicz, M., Beck, L. A., Hanifin, J. M., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.003 · Cited by 54 · see citing works
Rosacea associated with dupilumab therapy
Heibel, H. D., Hendricks, A. J., Foshee, J. P., & Shi, V. Y. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1624683 · Cited by 53 · see citing works
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
Bansal, A., Simpson, E. L., Paller, A. S., Siegfried, E. C., Blauvelt, A., de Bruin-Weller, M., Corren, J., Sher, L., Guttman-Yassky, E., Chen, Z., et al. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00577-1 · Cited by 52 · see citing works
Self-citationMalignancy risk in patients with atopic dermatitis: a population-based cohort study
Wan, J., Shin, D. B., Syed, M. N., Abuabara, K., Lemeshow, A. R., Fuxench, Z. C. C., & Gelfand, J. M. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad072 · Cited by 51 · see citing works
Adverse drug reactions to biologics
Scherer, K., Spoerl, D., & Bircher, A. J. (2010) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07339.x · Cited by 50 · see citing works
Schneeweiss, S., Doherty, M., Zhu, S., Funch, D., Schlienger, R., Fernández-Vidaurre, C., & Seeger, J. (2009) · Dermatology · doi:10.1159/000209289 · Cited by 48 · see citing works
Systemic and local immunological features of atopic dermatitis patients with ocular complications
Uchio, E., Miyakawa, K., Ikezawa, Z., & Ohno, S. (1998) · British Journal of Ophthalmology · doi:10.1136/bjo.82.1.82 · Cited by 48 · see citing works
Silverberg, J. I. (2014) · Pediatric Allergy and Immunology · doi:10.1111/pai.12315 · Cited by 46 · see citing works
Cork, M. J., Thaçi, D., Eichenfield, L. F., Arkwright, P. D., Chen, Z., Thomas, R. B., Kosloski, M. P., Dubost-Brama, A., Prescilla, R. P., Bansal, A., et al. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-01016-9 · Cited by 44 · see citing works
Self-citationCurrent and Future Biomarkers in Atopic Dermatitis
Thijs, J. L., de Bruin-Weller, M. S., & Hijnen, D. (2016) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2016.08.008 · Cited by 42 · see citing works
Jang, D. H., Heo, S., Kook, H. D., Lee, D. H., Jung, H. J., Park, M. Y., & Ahn, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-02950-4 · Cited by 33 · see citing works
Atopic dermatitis treatment: Current state of the art and emerging therapies
Silverberg, J. I. (2017) · Allergy and Asthma Proceedings · doi:10.2500/aap.2017.38.4054 · Cited by 32 · see citing works
Siegfried, E. C., Bieber, T. R. M., Simpson, E. L., Paller, A. S., Beck, L. A., Boguniewicz, M., Schneider, L. C., Khokhar, F. A., Chen, Z., Prescilla, R. P., et al. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00583-3 · Cited by 31 · see citing works
Self-citationGriffiths, C. E. M., de Bruin-Weller, M. S., Deleuran, M. S., Fargnoli, M. C., Staumont-Sallé, D., Hong, C.-H., Sánchez‐Carazo, J. L., Foley, P. A., Seo, S. J., Msihid, J., et al. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00558-0 · Cited by 30 · see citing works
Self-citationPaller, A. S., Wollenberg, A., Siegfried, E. C., Thaçi, D., Cork, M. J., Arkwright, P. D., Gooderham, M., Sun, X., O’Malley, J. T., Khokhar, F. A., et al. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00459-x · Cited by 29 · see citing works
Self-citationAtopic Dermatitis Yardstick update
Boguniewicz, M., Fonacier, L. S., Guttman‐Yassky, E., Ong, P. Y., & Silverberg, J. I. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.03.010 · Cited by 29 · see citing works
Salah, L. A., & Faergemann, J. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-1996 · Cited by 28 · see citing works
Simpson, E. L., Benedetto, A. D., Boguniewicz, M., Ong, P. Y., Lussier, S. J., Villarreal, M., Schneider, L. C., Paller, A. S., Guttman‐Yassky, E., Hanifin, J. M., et al. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.04.052 · Cited by 28 · see citing works
Atopic dermatitis and bone health: a systematic review
Mukovozov, I., Morra, D. E., Giustini, D., Tadrous, M., Cheung, A. M., & Drucker, A. M. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16895 · Cited by 26 · see citing works
Ahn, J., Lee, D. H., Na, C. H., Shim, D. H., Choi, Y. S., Jung, H. J., & Simpson, E. L. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18327 · Cited by 25 · see citing works
Hughes, C., Nathan, J., Mathew, L., Pink, A., Woolf, R., Smith, C. H., Menon, B. S., & Kirkham, B. W. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42558 · Cited by 22 · see citing works
Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin
Leung, D. Y. M., Bissonnette, R., Kreimer, S. D., Berdyshev, E. V., Bafna, S., Lyubchenko, T. A., Richers, B. N., Garcia, S. L., Ramirez-Gama, M. A., Hall, C. F., et al. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.03.020 · Cited by 21 · see citing works
Nakanishi, M., Tamagawa‐Mineoka, R., Arakawa, Y., Masuda, K., & Katoh, N. (2020) · Allergology International · doi:10.1016/j.alit.2020.07.001 · Cited by 20 · see citing works
McKenzie, P. L., Rangu, S. A., Treat, J. R., & Castelo‐Soccio, L. A. (2021) · Pediatric Dermatology · doi:10.1111/pde.14799 · Cited by 20 · see citing works
Facial Redness in Atopic Dermatitis Patients Treated With Dupilumab: A Case Series
Seok, S. H., An, J. H., Shin, J. U., Lee, H. J., Kim, D. H., Yoon, M. S., & Kim, H. J. (2020) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2020.12.6.1063 · Cited by 19 · see citing works
Simpson, E. L., Paller, A. S., Siegfried, E. C., Thaçi, D., Wollenberg, A., Cork, M. J., Marcoux, D., Huang, R., Chen, Z., Rossi, A. B., et al. (2021) · Europe PMC (PubMed Central) · doi:10.1007/s13555-021-00568-y · Cited by 19 · see citing works
Self-citationPaller, A. S., Siegfried, E. C., Cork, M. J., Wollenberg, A., Arkwright, P. D., González, M. E., Lockshin, B., Chen, Z., Bansal, A., Levit, N. A., et al. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00553-8 · Cited by 19 · see citing works
Self-citationStuver, R. N., Dusza, S. W., Epstein-Peterson, Z. D., Ghione, P., Horwitz, S. M., Johnson, W. T., Moskowitz, A. J., Myskowski, P. L., Pulitzer, M. P., & Geller, S. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20141 · Cited by 18 · see citing works
Facial erythema after the treatment of dupilumab in SLE patient
Jang, D. H., Lee, J. I., Bae, J. Y., Jung, H. J., Park, M. Y., & Ahn, J. (2020) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-020-00458-6 · Cited by 17 · see citing works
[Eye complications in atopic dermatitis].
Ohmachi, N., Sasabe, T., Kojima, M., Adachi, J., Endo, K., Fukuzumi, T., & Aoki, T. (1994) · PubMed · Cited by 15 · see citing works
Miyagaki, T., Okano, T., Nakajima, K., Mitsuishi, S., Kishi, A., Miyano, K., Takeuchi, S., & Kadono, T. (2021) · Dermatologic Therapy · doi:10.1111/dth.14888 · Cited by 14 · see citing works
Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis
Silverberg, J. I., Rubini, N. P. M., Pires, M. C., Rossi, A. B., Zhang, A., Chen, Z., Levit, N. A., Chao, J., Shumel, B., & Bagousse, G. B.-L. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.11.034 · Cited by 14 · see citing works
Self-citationAngioedema: A potential complication of dupilumab in atopic dermatitis
Fritz, A. L., Lacy, F. A., & Morrell, D. S. (2020) · Pediatric Dermatology · doi:10.1111/pde.14434 · Cited by 12 · see citing works
Napolitano, M., Fabbrocini, G., & Patruno, C. (2021) · Contact Dermatitis · doi:10.1111/cod.13898 · Cited by 10 · see citing works
Dupilumab Facial Redness: Histologic Characterization on a Series of four Cases
Dybała, A., Sernicola, A., Gomes, V., Carnicelli, G., Muharremi, R., & Grieco, T. (2021) · Immunotherapy · doi:10.2217/imt-2021-0122 · Cited by 10 · see citing works
Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus
Eichenfield, L. F., Boguniewicz, M., Lauren, C. T., Leung, D. Y. M., Levy, M. L., Schneider, L. C., Siegfried, E. C., Tom, W. L., & Paller, A. S. (2024) · Dermatology · doi:10.1159/000540920 · Cited by 9 · see citing works
Droitcourt, C., Vittrup, I., Dupuy, A., Egeberg, A., & Thyssen, J. P. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19825 · Cited by 8 · see citing works
Silverberg, J. I., Simpson, E. L., Weidinger, S., Barbarot, S., Brignoli, L., Mnif, T., Saba, G., Eckert, L., Rossi, A. B., Delevry, D., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.12.149 · Cited by 8 · see citing works
Self-citationIs dupilumab use in atopic dermatitis associated with cutaneous T-cell lymphoma?
Ong, P. Y. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.02.002 · Cited by 6 · see citing works
666 Effect of dupilumab on the host-microbe interface in atopic dermatitis
Beck, L. A., Boguniewicz, M., Hatta, T., Fuxench, Z. C. C., Simpson, E. L., Benedetto, A. D., Ko, J., Ong, P. Y., Yoshida, T., Gallo, R. L., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.02.696 · Cited by 3 · see citing works
Nguyen, T. V., Marcus, A. F., Sinnott, S., Coleman, A., Peralta, C., Levy, S., Kushwaha, P., Sierka, D., Ardeleanu, M., & Rossi, A. B. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.08.082 · Cited by 2 · see citing works
Self-citationAsbell, P. A., Akpek, E. K., Chamberlain, W., Chen, Z., Coleman, A., Rossi, A. B., & Shumel, B. S. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae266.061 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- [29]ICH Harmonised Tripartite Guideline: Clinical safety data management: definitions and standards for expedited reporting E2A. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1994. https://database.ich.org/sites/default/files/E2A_Guideline.pdf. Accessed 12 Nov 2024.
- [76]Goleva E, Berdyshev E, Kreimer S, et al. Dupilumab inhibits expression of fibronectin and fibrinogen, skin proteins that regulate Staphylococcus aureus adhesion to atopic dermatitis skin. 12th Georg Rajka International Symposium on Atopic Dermatitis, Oct 17–19, 2022; hybrid congress: virtual and Montreal, Quebec, Canada.
- [113]Allinne J, Scott G, Birchard D, Asrat S, Nagashima K, Le Floc’h A, et al. Broader impact of IL-4Rα blockade than IL-5 blockade on mediators of type 2 inflammation and lung pathology in a house dust mite-induced asthma mouse model. Am J Respir Crit Care Med. 2019;199:A5555.
Cited by
Sorted by citations
Amatore, F., Neildez, M., de Masson, A., Battistella, M., Tauber, M., Oro, S., Droitcourt, C., Staumont-Sallé, D., & Beylot-Barry, M. (2026) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70407 · Cited by 4 · see citing works
Hamilton, J. D., Ferreira, M. A. R., Lim, W. K., Sidore, C., Wipperman, M. F., Ge, W., Song, X., Xia, C., Horowitz, J. E., Hooper, A. T., et al. (2026) · Allergy · doi:10.1111/all.70380 · Cited by 3 · see citing works
Self-citationIndolfi, C., Klain, A., Dinardo, G., Colosimo, S., Ferrara, S., Grella, C., Galdiero, M., Filippis, A. D., Fiore, V., & del Giudice, M. M. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1836967 · Cited by 2 · see citing works
Revolutionizing dermatopathology using AI in skin diagnostics: scoping review
Rammal, R., Mohy U Din, A., & Alam, T. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1614681 · Cited by 1 · see citing works
Calcineurin Inhibitors in Atopic Dermatitis: Balancing Tradition with Emerging Therapeutics
Kumar, R., Rabbani, S. A., El‐Tanani, M., Sharma, S., & Saini, M. (2026) · Medical Sciences · doi:10.3390/medsci14020297 · Cited by 1 · see citing works
Cho, Y., Chan, T. C.-C., Chen, W., Chu, H.-S., & Chu, C. (2026) · Allergology International · doi:10.1016/j.alit.2026.04.009 · Cited by 1 · see citing works
Alotaibi, M. A., Alhelal, S. M., Alotaibi, N., & Alsudairy, F. (2026) · Case Reports in Dermatological Medicine · doi:10.1155/crdm/8570980 · Cited by 1 · see citing works
Yan, L., Cen, H., Yi, B., & Fang, Y. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05546-9 · Cited by 1 · see citing works
IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?
Ippoliti, E., Boeti, L., D'Amore, A., Cannizzaro, M. V., Peris, K., & Gori, N. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2628688 · Cited by 1 · see citing works
Langley, R. G., Gherardi, G., Coleman, A., Ardeleanu, M., Marco, A. R., Levy, S., Bansal, A., Chen, Z., Rossi, A. B., Shumel, B. S., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03606-3
Self-citationBenedetto, A. D., Boguniewicz, M., Fonacier, L. S., Silverberg, J., Abuabara, K., & Ong, P. Y. (2026) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2026.05.028
Bowe, S., O’Reilly, S., Murphy, M., O’Mahony, A., Harney, S., Zulquernain, S. A., & Bourke, J. (2026) · Current Oncology · doi:10.3390/curroncol33080445
Benedetto, A. D., & Mannava, K. A. (2026) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70542
Liu, S., Cao, Y., Song, H., Tian, Z., & Li, X. (2026) · Journal of Asthma · doi:10.1080/02770903.2026.2721186
From Barrier Disruption and Immune Dysregulation to Targeted Therapies in Atopic Dermatitis
Luo, X., Li, Y., Feng, Y., Wang, Y., Li, Z., Zhang, Y., & Shen, P. (2026) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-026-09198-8
Wei, J., & Huang, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1906235
Dupilumab for severe atopic dermatitis in a 6-month-old infant: a case report
Pełszyk, A., Pogonowska, M., Królikowska, K., Stasiak, O., & Rustecka, A. (2026) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2026.0030
Dual Remission of Atopic Dermatitis and Frequently Relapsing Nephrotic Syndrome With Dupilumab
Dastrevigne, I., Terzic, J., Lipsker, D. M., & Braud, A. (2026) · PEDIATRICS · doi:10.1542/peds.2026-077217
- Authors
- Langley, R. G., Gherardi, G., Coleman, A., Ardeleanu, M., Rodríguez-Marco, A., Levy, S., Bansal, A., Chen, Z., Rossi, A. B., Shumel, B., & Khokhar, F. A.
- Affiliations
- Dalhousie University (CA)
- Sanofi (United Kingdom) (GB)
- Regeneron (United States) (US)
- Corresponding author
- Langley, Richard G.
- ORCID
- Venue
- American Journal of Clinical Dermatology
- Published
- 2025-09-24
- Volume
- 26
- Issue
- 6
- Pages
- 981-1002
- ISSN
- 1175-0561 (ISSN-L)
- 1179-1888
- PMC
- PMC12615541
- OpenAlex
- W4414459865
- Cited by
- 18
- References
- 106
- Citations by year
- 2026: 18
- FWCI
- 17.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Clinical Dermatology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Regeneron Pharmaceuticals
- Sanofi
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Keywords
- dupilumab, atopic dermatitis, drug safety, treatment-emergent adverse events, children and adolescents, topical corticosteroids, injection site reactions, conjunctivitis, serious infections, type 2 inflammation, serious adverse events, quality of life
- MeSH terms
- Adolescent, Adult, Age Factors, Child, Child, Preschool, Dermatitis, Atopic, Dermatologic Agents, Female, Humans, Infant, Male, Quality of Life, Severity of Illness Index, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase III as Topic, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
